LON:HIK Hikma Pharmaceuticals - HIK Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. GBX 1,675 -5.50 (-0.33%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range 1,669▼ 1,69550-Day Range 1,631.43▼ 1,808.5052-Week Range 1,174.50▼ 2,095.45Volume284,841 shsAverage Volume410,705 shsMarket Capitalization£3.69 billionP/E Ratio2,463.24Dividend Yield2.75%Price TargetGBX 1,882 ProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlinesSustainability Hikma Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside12.4% UpsideGBX 1,882 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainability-2.61Upright™ Environmental ScoreNews Sentiment0.12Based on 9 Articles This WeekInsider TradingAcquiring Shares£1.70 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 stars 3.3 Analyst's Opinion Consensus RatingHikma Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 1,882, Hikma Pharmaceuticals has a forecasted upside of 12.4% from its current price of GBX 1,675.Amount of Analyst CoverageHikma Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HIK. Previous Next 0.8 Dividend Strength Dividend YieldHikma Pharmaceuticals pays a meaningful dividend of 2.76%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthHikma Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Hikma Pharmaceuticals is 6,764.71%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHikma Pharmaceuticals has received a 48.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Abiraterone", "Cancer medication (L01)", "Isosorbide dinitrate", and "HIV medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Hikma Pharmaceuticals is -2.61. Previous Next 2.3 News and Social Media Coverage News SentimentHikma Pharmaceuticals has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Hikma Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Hikma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hikma Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought £17,030 in company stock and sold GBX 0 in company stock.Percentage Held by Insiders29.63% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 39.72% of the stock of Hikma Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Hikma Pharmaceuticals is 2,463.24, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 127.91.Price to Earnings Ratio vs. SectorThe P/E ratio of Hikma Pharmaceuticals is 2,463.24, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 112.72.Price to Earnings Growth RatioHikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHikma Pharmaceuticals has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Hikma Pharmaceuticals (LON:HIK) StockHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.Read More Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HIK Stock News HeadlinesMarch 31, 2023 | uk.finance.yahoo.comNaloxone Spray Global Market Report 2023March 29, 2023 | marketwatch.comEsmolol Hydrochloride Market Application, Product, Sales and Forecast 2023-2031April 2, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. March 29, 2023 | marketwatch.comInhalation & Nasal Sprays Generic Drugs Market by 2031March 29, 2023 | americanbankingnews.comHikma Pharmaceuticals PLC (LON:HIK) Receives GBX 1,882 Consensus Price Target from AnalystsMarch 28, 2023 | marketwatch.comOpioid Use Disorder Market Size, Share, Growth, Analysis, Trends and Forecast to 2031March 28, 2023 | marketwatch.comZolpidem Tartrate Market 2023 Size and Forecast to 2030March 28, 2023 | marketwatch.comAlprostadil Injection Market Size and Forecast till 2030April 2, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. March 28, 2023 | marketwatch.comRanitidine (Zantac) Market Growing Demand and Trends 2023 to 2031March 27, 2023 | marketwatch.comZolpidem Tartrate Market Share and Forecast till 2031March 24, 2023 | marketwatch.comCancer Cachexia Therapeutics Market Size, Share and Forecast 2031March 21, 2023 | marketwatch.comPromethazine Hydrochloride Injection Market 2023 Future Trends and Forecast 2029 | Sanofi, Pfizer, Hikma PharmaceuticalsMarch 21, 2023 | marketwatch.comAtropine Sulfate Injection Market Share, Size, Financial Summaries Analysis from 2023 to 2029 | Pfizer, American Regent, Hikma PharmaceuticalsMarch 21, 2023 | marketwatch.comCyclophosphamide Market Growth and Forecast till 2028March 21, 2023 | americanbankingnews.comHikma Pharmaceuticals PLC (LON:HIK) Increases Dividend to $0.37 Per ShareMarch 15, 2023 | uk.finance.yahoo.com$426.3+ Billion Worldwide Generic Pharmaceuticals Industry to 2032: North America was the Largest Region in 2022March 15, 2023 | marketwatch.comGlobal Zolpidem Tartrate Market Size by Type (Sublingual Tablets, Oral Spray) Forecast from 2023 to 2028March 15, 2023 | marketwatch.comAzelastine Market Share and Forecast till 2028March 15, 2023 | marketwatch.comTotal Intravenous Anesthesia (TIVA) Market Significant Growth and Revenue Till 2028March 14, 2023 | marketwatch.comHikma Pharmaceuticals rises Tuesday, still underperforms marketMarch 14, 2023 | msn.comQatar's Health Minister Ranks 3rd Place in Forbes List 2023March 14, 2023 | msn.comForbes Middle East Reveals Top 100 Healthcare Leaders 2023 ListMarch 14, 2023 | marketwatch.comAnaesthetic Medicines Market 2023 Expected to Reach Significant Rate by 2028March 14, 2023 | marketwatch.comGeneric Injectables Market : Regulations, Strategic Industry Growth Analysis, Market Size Between 2023 to 2030March 13, 2023 | marketwatch.comCold Sore Treatment Market Application, Product, Sales and Forecast 2023-2028March 13, 2023 | msn.comForbes Middle East Unveils The Region’s Top 100 Healthcare LeadersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HIK Company Calendar Ex-Dividend for 5/5 Dividend3/23/2023Today4/01/2023Dividend Payable5/05/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:HIK CUSIPN/A CIKN/A Webwww.hikma.com Phone+44-20-73992760FaxN/AEmployees8,700Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 1,882 High Stock Price ForecastGBX 2,100 Low Stock Price ForecastGBX 1,700 Forecasted Upside/Downside+12.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.68 Trailing P/E Ratio2,463.24 Forward P/E Ratio18.13 P/E Growth2.38Net Income£188 million Net Margins7.47% Pretax MarginN/A Return on Equity8.28% Return on Assets8.35% Debt Debt-to-Equity Ratio59.73 Current Ratio1.86 Quick Ratio1.27 Sales & Book Value Annual Sales£2.52 billion Price / Sales1.46 Cash FlowGBX 200.87 per share Price / Cash Flow8.34 Book ValueGBX 969 per share Price / Book1.73Miscellaneous Outstanding Shares220,260,000Free FloatN/AMarket Cap£3.69 billion OptionableNot Optionable Beta0.31 Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 65)Exec. Chairman & CEO Comp: $2.71MMr. Mazen Samih Taleb Darwazah (Age 64)Exec. Vice Chairman & Pres of MENA Comp: $2.11MMr. Khalid Waleed Hosny Al Nabilsi (Age 50)Chief Financial Officer Mr. Hussein ArkhaghaCompany Sec. & Chief CounselMr. Bassam Wael Rushdi Kanaan CFA (Age 57)CPA, Exec. VP of Corp. Devel. and M&A Ms. Susan RingdalExec. VP of Strategic Planning & Global AffairsMs. Majda LabadiExec. VP of Organisational Devel.Mr. Riad MishlawiPres of InjectablesMr. Brian HoffmannPres of GenericsMr. Samuel ParkGlobal Head of Intellectual Property (IP) & Gen. Counsel for USMore ExecutivesKey CompetitorsMediclinic InternationalLON:MDCBTGLON:BTGDechra PharmaceuticalsLON:DPHAbcamLON:ABCConvaTec GroupLON:CTECView All CompetitorsInsidersDeneen VojtaBought 1,000 shares on 1/17/2023Total: £1.70 M ($1,703.00/share)View All Insider Transactions HIK Stock - Frequently Asked Questions Should I buy or sell Hikma Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HIK shares. View HIK analyst ratings or view top-rated stocks. What is Hikma Pharmaceuticals' stock price forecast for 2023? 6 equities research analysts have issued 12 month target prices for Hikma Pharmaceuticals' shares. Their HIK share price forecasts range from GBX 1,700 to GBX 2,100. On average, they anticipate the company's stock price to reach GBX 1,882 in the next year. This suggests a possible upside of 12.4% from the stock's current price. View analysts price targets for HIK or view top-rated stocks among Wall Street analysts. How have HIK shares performed in 2023? Hikma Pharmaceuticals' stock was trading at GBX 1,552 on January 1st, 2023. Since then, HIK stock has increased by 7.9% and is now trading at GBX 1,675. View the best growth stocks for 2023 here. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals announced a dividend on Thursday, February 23rd. Stockholders of record on Thursday, March 23rd will be given a dividend of GBX 0.37 per share on Friday, May 5th. This represents a dividend yield of 1.74%. The ex-dividend date of this dividend is Thursday, March 23rd. This is an increase from the stock's previous dividend of GBX 0.19. The official announcement can be seen at this link. Read our dividend analysis for HIK. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 46 per share and currently has a dividend yield of 2.76%. The dividend payout ratio is 6,764.71%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for HIK. What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC). What is Hikma Pharmaceuticals' stock symbol? Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK." How do I buy shares of Hikma Pharmaceuticals? Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Hikma Pharmaceuticals' stock price today? One share of HIK stock can currently be purchased for approximately GBX 1,675. How much money does Hikma Pharmaceuticals make? Hikma Pharmaceuticals (LON:HIK) has a market capitalization of £3.69 billion and generates £2.52 billion in revenue each year. The company earns £188 million in net income (profit) each year or GBX 0.68 on an earnings per share basis. How many employees does Hikma Pharmaceuticals have? The company employs 8,700 workers across the globe. How can I contact Hikma Pharmaceuticals? Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at +44-20-73992760. This page (LON:HIK) was last updated on 4/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.